开源证券认为，差异化战略是重组胶原蛋白企业脱颖而出关键，本次巨子生物在XVII型胶原领域取得的专利成果，正是对“多元布局”的印证。展望未来，天然胶原足有29种，不同型别，甚至同一型别的不同片段都有可能在人体中发挥出不同功能，重组胶原蛋白产业具备较高天花板，坚定看好重组胶原行业未来发展。Juzi Biotechnology (02367) rose more than 5%, as of the time of publication, rose 5.17%, reported HK$37.6, turnover of 0.141 billion HKD.
According to the Smart Finance APP, Juzi Biotechnology (02367) rose more than 5%, as of the time of publication, rose 5.17%, reported HK$37.6, turnover of 0.141 billion HKD.
On the news side, recently, Juzi Biotechnology announced that its exclusive patent "Recombinant human type XVII collagen, its preparation method and application" has been officially authorized by the National Intellectual Property Office. This invention selects a truncated protein (p978-p1084) from type XVII collagen, non-G-X-Y structure region, which is rich in serine and has good biological activities such as follicle repair and hair regeneration. It is expected to play an important role in scalp care, hair care, facial care, etc.
Kaiyuan Securities believes that differentiated strategy is the key to the success of recombinant collagen protein enterprises. The patent achievements in the field of type XVII collagen obtained by Juzi Biotechnology this time are the affirmation of "diversified layout". Looking ahead, there are 29 types of natural collagen, different types, and even different segments of the same type may have different functions in the human body. The recombinant collagen protein industry has a high ceiling, and it is bullish on the future development of the recombinant collagen industry.
